PSMA therapy is a targeted treatment for metastatic prostate cancer that uses radioligand therapy to slow disease progression ...

Metastatic prostate cancer occurs when the disease extends beyond the prostate, spreading to other parts of the body. It can be a scary and intimating diagnosis, but there are many good treatment ...

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer -such as ...

Over the past year alone, 4 major clinical trials have redefined frontline HSPC management. ARANOTE ( NCT02799602) v alidated ...

Researchers have found a potential way to attack prostate cancers that evade treatment by changing their cellular identity.

Opevesostat (Merck). A first-in-class CYP11A1 inhibitor that shuts down androgen production at its source, opevesostat is in two phase 3 trials, OMAHA-003 and OMAHA-004, for metastatic ...

Hormone Therapy Might Be Unnecessary For Some Prostate Cancer Patients By Dennis Thompson HealthDay ReporterMONDAY, March 2, 2026 (HealthDay News) — Some men who’ve had surgery for prostate cancer can ...

After 6 months of hormone therapy, men with prostate cancer showed worsening lipid profiles, with 21% showing increased risk of cardiovascular disease based on general population tools. Men receiving ...

Combining the targeted therapy olaparib with an additional immunotherapy may improve immune response in a subgroup of ...